Loading…

Publications

Kandula T, Farrrar MA, Cohn RJ, Mizrahi D, Carey K, Johnston K, Kiernan MC, Krishnan AV, Park SB. (2018). Chemotherapy-induced peripheral neuropathy in long-term survivors of childhood cancer: neurophysiological, functional and patient reported outcomes. JAMA Neurology.

Park SB. (2018). Chemotherapy-induced peripheral neuropathy: Highlighting unmet needs. Journal of Neurology Neurosurgery and Psychiatry. Epub ahead of print.

Park SB, Kiernan MC. (2018). Oxaliplatin and neuropathy: A role for sodium channels. Clinical Neurophysiology. 129(3):670-671.

Tonkin RS, Bowles C, Perera CJ, Keating BA, Makker PGS, Duffy SS, Lees JG, Tran C, Don AS, Fath T, Liu L, O’Carroll SJ, Nicholson LFB, Green CR, Gorrie C, Moalem-Taylor G. (2018) Attenuation of mechanical pain hypersensitivity by treatment with Peptide5, a connexin-43 mimetic peptide, involves inhibition of NLRP3 inflammasome in nerve-injured mice. Exp Neurol. 300:1-12. DOI: 10.1016/j.expneurol.2017.10.016

Feather CE, Lees JG, Makker PGS, Goldstein D, Kwok JB, Moalem-Taylor G, Polly P. Oxaliplatin induces muscle loss and muscle-specific molecular changes in mice. Muscle and Nerve. Advance publication online: 2017 Sep 7. doi: 10.1002/mus.25966.

Kandula T, Farrar MA, Krishnan AV, Murray J, Timmins HC, Goldstein D, Lin CS-Y, Kiernan MC, Park SB. (2017) Multimodal quantitative examination of nerve function in colorectal cancer patients prior to chemotherapy. Muscle and Nerve. Advance publication online: 2017 Sep 7. doi: 10.1002/mus.25968

Park SB, Kwok JB, Asher R, Lee CK, Beale P, Selle F, Friedlander M. (2017) Clinical and genetic predictors of paclitaxel neurotoxicity based on patient versus clinician reported incidence and severity of neurotoxicity in the ICON7 trial. Annals of Oncology. 28(11): 2733-2740.

McCrary JM, Goldstein D, Boyle F, Cox K, Grimison P, Kiernan MC, Krishnan AV, Lewis CR, Webber K, Baron-Hay S, Horvath L, Park SB (2017). Optimal clinical assessment strategies for chemotherapy-induced peripheral neuropathy (CIPN): A systematic review and delphi survey. Support Care Cancer. 25(11): 3485-3493.

Kandula T, Farrar MA, Kiernan MC, Krishnan AV, Goldstein D, Horvath L, Grimison P, Boyle F, Baron-Hay S, Park SB (2017). Neurophysiological and clinical outcomes in chemotherapy-induced neuropathy in cancer. Clin Neurophysiol. 128(7):1166-1175.

Lees JG, Makker PG, Tonkin RS, Abdulla M, Park SB, Goldstein D, Moalem-Taylor G (2017). Immune-mediated processes implicated in chemotherapy-induced peripheral neuropathy. Eur J Cancer. 73:22-29.

Makker PG, Duffy SS, Lees JG, Perera CJ, Tonkin RS, Botovsky O, Park SB, Goldstein D, Moalem-Taylor G (2017). Characterisation of immune and neuroinflammatory changes associated with chemotherapy-induced peripheral neuropathy. PLOS One. 12(1): e0170814.

Kandula T, Park SB, Cohn RJ, Farrar MA. (2016) Pediatric chemotherapy induced peripheral neuropathy: a systematic review of current knowledge. Cancer Treatment Reviews. 50: 118-128.

Krishnan AV, Park SB. (2014). Chemotherapy-induced peripheral neuropathy: the end of the beginning? Journal of Neurology, Neurosurgery and Psychiatry. 85:359. Invited commentary PMID: 23833264

Park SB, Kwok JB, Loy CT, Friedlander ML, Lin CS, Krishnan AV, Lewis CR, Kiernan MC. (2014). Paclitaxel-induced neuropathy: potential association of MAPT and GSK3B genotypes. BMC Cancer. 22;14:993. doi: 10.1186/1471-2407-14-993.

Park SB, Goldstein D, Krishnan AV, Lin CS, Friedlander ML, Cassidy J, Koltzenburg M, Kiernan MC. (2013). Chemotherapy-induced peripheral neurotoxicity: A critical analysis. CA A Cancer Journal for Clinicians. 63:419-437 PMID: 24590861

Bennett BK, Park SB, Lin CS, Friedlander ML, Kiernan MC, Goldstein D. (2012). Impact of oxaliplatin-induced neuropathy: a patient perspective. Supportive Care in Cancer. 20(11):2959-67. PMID: 22426503

Park SB, Koltzenburg M, Lin CS, Kiernan MC. (2012). Longitudinal assessment of oxaliplatin-induced neuropathy. Neurology 78(2): 152. PMID: 22232054

Park SB, Lin CS, Kiernan MC. (2012) Nerve excitability assessment in chemotherapy-induced neurotoxicity. Journal of Visualized Experiments 62: 3439. PMID: 22565594

Park SB, Goldstein D, Lin CSY, Krishnan AV, Friedlander ML & Kiernan MC (2011) Neuroprotection for Oxaliplatin-induced neurotoxicity: What happened to objective assessment? Journal of Clinical Oncology.29 (18): e553-554. PMID: 21606425

Park SB, Lin CSY, Krishnan AV, Goldstein D, Friedlander ML & Kiernan MC (2011) Dose effects of oxaliplatin on persistent and transient Na+ conductances and the development of Neurotoxicity. PLoS ONE 6(4): e18469. PMID: 21494615

Park SB, Lin CS, Krishnan AV, Goldstein D, Friedlander ML & Kiernan MC (2011) Long-term Neuropathy after Oxaliplatin Treatment: Challenging the Dictum of Reversibility? The Oncologist.16: 708-716. PMID: 21478275

Park SB, Lin CS, Krishnan AV, Goldstein D, Friedlander ML, & Kiernan MC. (2011) Utilizing natural activity to dissect the pathophysiology of acute oxaliplatin-induced neuropathy. Experimental Neurology. 227(1): 120-127. PMID: 20965170

Park SB, Lin CS, Krishnan AV & Kiernan MC (2011) The contributions of SK3 polymorphisms to acute oxaliplatin-induced neurotoxicity: Direct or indirect effects? Cancer, Chemotherapy, and Pharmcology 67(5):1189-1190. PMID: 21327679

Park SB, Lin CS, Krishnan AV, Lewis CR, Friedlander ML, & Kiernan MC. (2011) Early, progressive, and sustained dysfunction of sensory axons underlies paclitaxel-induced neuropathy. Muscle and Nerve. 43(3): 367-374 PMID: 21321953

Park SB, Goldstein D, Lin CSY, Krishnan AV, Friedlander ML & Kiernan MC. (2009) Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity. Journal of Clinical Oncology27 (8): 1243-1249. PMID: 19164207

Park SB, Lin CSY, Krishnan AV, Goldstein D, Friedlander ML & Kiernan MC. (2009) Oxaliplatin-induced Lhermitte’s phenomenon as a manifestation of severe generalized nerve dysfunction. Oncology 77:342 – 348. PMID: 20016227

Park SB, Lin CS, Krishnan AV, Goldstein D, Friedlander ML & Kiernan MC. (2009). Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. Brain 132: 2712-2723. PMID: 19745023

Krishnan AV, Lin CS, Park SB & Kiernan MC. (2008) Assessment of nerve excitability in toxic and metabolic neuropathies. Journal of the Peripheral Nervous System 13(1): 7-26.

Park SB, Krishnan AV, Lin CSY, Goldstein D, Friedlander ML & Kiernan MC. (2008) Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies. Current Medicinal Chemistry 15(29):3081 – 3094. Invited Review

Kiernan MC. (2007) The pain with platinum: oxaliplatin and neuropathy. Eur J Cancer. 43(18):2631-3.

Kiernan MC, Krishnan AV. (2006) The pathophysiology of oxaliplatin-induced neurotoxicity. Curr Med Chem. 13(24):2901-7.

Krishnan AV, Goldstein D, Friedlander M, Kiernan MC. (2006). Oxaliplatin and axonal Na+ channel function in vivo. Clin Cancer Res. 1;12(15):4481-4.

Mitchell PL, Goldstein D, Michael M, Beale P, Friedlander M, Zalcberg J, White S, Thomson JA, Clarke S. (2006). Addition of gabapentin to a modified FOLFOX regimen does not reduce oxaliplatin-induced neurotoxicity. Clin Colorectal Cancer. 6(2):146-51.

Krishnan AV, Goldstein D, Friedlander M, Kiernan MC. (2005). Oxaliplatin-induced neurotoxicity and the development of neuropathy. Muscle Nerve. 32(1):51-60.